Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.6K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.6K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.9K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.9K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

1.0K
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
1.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

748
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
748

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Body mass index and prevalence of low back pain: correlation in a large, contemporary cohort.

Pain medicine (Malden, Mass.)·2025
Same author

Perspectives on treatment decision-making across racial groups in adults with degenerative lumbar disease - A pilot study.

Interventional pain medicine·2025
Same author

X-ray Prediction of Magnetic Resonance Imaging in Low Back Pain.

American journal of physical medicine & rehabilitation·2025
Same author

Pharmacotherapy for Spine-Related Pain in Older Adults.

Drugs & aging·2022
Same author

Three-way telemedicine visits in resident clinic.

Medical education·2020
Same author

Rapid Dissemination of Protocols for Managing Neurology Inpatients with COVID-19.

Annals of neurology·2020

Related Experiment Video

Updated: Mar 8, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.8K

Triptans and migraine: advances in use, administration, formulation, and development.

Amanda E Macone1, Michael D Perloff1

  • 1a Department of Neurology , Boston University School of Medicine, Boston University Medical Center , Boston , MA , USA.

Expert Opinion on Pharmacotherapy
|January 29, 2017
PubMed
Summary

Recent triptan research shows advances in formulations and combination therapies for migraines. While some new options offer benefits, their higher cost and potential side effects warrant consideration against established generic triptans.

Keywords:
Triptanadministrationdevicedexketoprofenfrovatriptanlasmiditanmenstrual migrainemigrainenaproxennaratriptansumatriptan

More Related Videos

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

10.0K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.3K

Related Experiment Videos

Last Updated: Mar 8, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.8K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

10.0K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.3K

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Recent triptan development focuses on novel administration, combination therapies, and targeting specific serotonin receptor subtypes (5HTf).
  • Research reviewed clinical trials (Class 1 or 2 evidence) from 2011-2016 for migraine treatment advancements.

Purpose of the Study:

  • To review clinical triptan research, analyzing recent advancements in migraine therapy.
  • To assess the efficacy, administration methods, and adverse reactions of new triptan formulations and agents.

Main Methods:

  • Systematic review of EMBASE and PUBMED databases.
  • Analysis focused on clinical trials with a high level of evidence (Class 1 or 2).
  • Data collected from January 1, 2011, to June 29, 2016.

Main Results:

  • Advances include improved drug combinations and administration devices enhancing ease of use and potentially reducing adverse reactions.
  • Some novel agents targeting 5HTf receptors avoid vascular side effects but may have limited clinical use due to adverse reactions.
  • Long half-life triptans (frovatriptan, naratriptan) show promise for menstrual-related migraines.

Conclusions:

  • New triptan developments offer advantages in migraine therapy and patient preference but come at a significantly higher cost than generic options.
  • Future triptan advances are desired for high efficacy, reduced adverse drug reactions (ADRs), and lower cost, building on established 5HT1b/d triptans.